S

Supernus Pharmaceuticals
D

SUPN

35.400
USD
-0.86
(-2.37%)
مغلق
حجم التداول
7,304
الربح لكل سهم
1
العائد الربحي
-
P/E
33
حجم السوق
1,954,762,264
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.520
    (-2.99%)
    16.900 USD
    ALNY
    ALNY
    -8.630
    (-3.50%)
    237.920 USD
    A
    AVDL
    -0.410
    (-3.82%)
    10.310 USD
    B
    BPMC
    -4.690
    (-4.86%)
    91.790 USD
    ILMN
    ILMN
    -9.110
    (-6.37%)
    133.990 USD
    I
    IONS
    -1.430
    (-3.79%)
    36.260 USD
    N
    NBIX
    -1.030
    (-0.75%)
    135.540 USD
    S
    SGEN
    0
    (0%)
    0.000000 USD
    VRTX
    VRTX
    -21.90
    (-4.67%)
    447.46 USD
    المزيد
الأخبار

العنوان: Supernus Pharmaceuticals

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia inPD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.